# US 2024/0002949 A1 · Panel of mirna biomarkers for diagnosis of ovarian cancer, method for in vitro diagnosis of ovarian cancer, uses of panel of mirna biomarkers for in vitro diagnosis of ovarian cancer and test for in vitro diagnosis of ovarian cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002949 A1
- Document ID: US20240002949A1
- Status: Published application
- Kind: A1
- Application number: 18/252,634
- Filed: 2020-11-11
- Published: 2024-01-04
- Earliest claimed: 2020-11-11
- Assignees: Uniwersytet Medyczny W Bialymstoku
- Applicants: Uniwersytet Medyczny W Bialymstoku
- Inventors: Magdalena NIEMIRA; Anna EROL; Jacek Adam KRETOWSKI
- Web page: https://patentgrep.com/patent/US20240002949A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention relates to a panel of miRNA biomarkers for in vitro diagnosis of ovarian cancer, a method for in vitro diagnosis of ovarian cancer, uses of a panel of miRNA biomarkers for in vitro diagnosis of ovarian cancer for use in an in vitro diagnostic screening assay for the presence of ovarian cancer, for assessing the effectiveness of ovarian cancer treatment, for monitoring response to ovarian cancer treatment and for predicting recurrence of ovarian cancer after a completed ovarian cancer treatment, as well as a test for in vitro diagnosis of ovarian cancer.

## Claims

### Claim 1

A diagnostic panel of miRNA biomarkers comprising miR-1246 and miR-150-5p.

### Claim 2

(canceled)

### Claim 3

A method for in vitro diagnosis of ovarian cancer in a subject, characterized in that it comprises the following steps:
i) determining the expression level of a panel of two miRNA biomarkers: miR-1246 and miR-150-5p in a sample from a subject and
ii) comparing the levels determined in step i) with the expression levels of miR-1246 and miR-150-5p in a subject without ovarian cancer, wherein the comparison provides a diagnostic indicator determining whether the subject has ovarian cancer.

### Claim 4 (depends on 3)

The method according to claim 3, characterized in that an increase in the miR-1246 expression level relative to the miR-1246 expression level in a subject without ovarian cancer and a decrease in the miR-150-5p expression level relative to the miR-150-5p expression level in a subject without ovarian cancer indicate ovarian cancer in the subject.

### Claim 5 (depends on 3)

The method according to claim 3, characterized in that the expression levels are normalized levels.

### Claim 6 (depends on 3)

The method according to claim 3, characterized in that a comparison of the expression levels is made with the use of a diagnostic classification model which classifies a sample as a sample from a subject with ovarian cancer or a sample from a subject without ovarian cancer.

### Claim 7 (depends on 6)

The method according to claim 6, characterized in that a diagnostic classification model compares the expression levels with the use of a data set comprising data on the expression level of a panel of miRNA markers comprising miR-1246 and miR-150-5p.

### Claim 8 (depends on 1)

The method according to claim 1, characterized in that the expression level of a panel of miRNA biomarkers is determined with the use of a method for measuring the expression selected from quantitative reverse transcription and polymerase chain reaction (qPCR).

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 3)

The method according to claim 3, characterized in that a sample is a serum sample.

### Claim 15 (depends on 3)

The method according to claim 3, characterized in that ovarian cancer is high-grade serous ovarian cancer.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

A method of treating ovarian cancer in a subject comprising monitoring response to ovarian cancer treatment by
i) determining the expression level of a panel of two miRNA biomarkers: miR-1246 and miR-150-5p in a sample from a subject after ovarian cancer treatment, and
ii) comparing the levels determined in step i) with the expression levels of miR-1246 and miR-150-5p in the subject before ovarian cancer treatment, wherein the comparison provides an indicator of the subject's response to the ovarian cancer treatment for adjustment of the ovarian cancer treatment.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 3)

A test for in vitro diagnosis of ovarian cancer or for determining recurrence of ovarian cancer after competed ovarian cancer treatment, characterized in that it comprises means for quantitative determination of the expression level of a panel of two miRNA biomarkers: miR-1246 and miR-150-5p and instructions for carrying out the method according to claim 3.

### Claim 22 (depends on 21)

The test for the diagnosis according to claim 21, characterized in that as means for the quantitative determination of the expression of miRNA biomarkers: miR-1246 and miR-150-5p it comprises reactants and primers for amplification in RT-qPCR reaction.

### Claim 23 (depends on 22)

The test for the diagnosis according to claim 22, characterized in that it further comprises means for quantitative determination of the expression of a reference miRNA, preferably a panel of miR-103-3p and/or miR-199b-5p.

### Claim 24 (depends on 8)

The method of claim 8, wherein the expression level of a panel of miRNA biomarkers is determined with the use of a real-time analysis of product quantity (RT-qPCR), NanoString or microarray method.

### Claim 25 (depends on 24)

The method according to claim 24, characterized in that a diagnostic classification model uses for the classification an optimal cut-off point selected from: 0.1-0.8 in the case of expression measurement by RT-qPCR method; 0.3-0.9 in the case of expression measurement by NanoString method and the value of in the case of expression measurement with the use of microarray.

### Claim 26 (depends on 25)

The method according to claim 25, characterized in that the RT-qPCR method is used for determination of the miRNA expression level.

### Claim 27 (depends on 26)

The method according to claim 26, characterized in that the expression level of a reference miRNA, preferably miR-103-3p and/or miR-199b-5p, is used for normalization of results.

### Claim 28 (depends on 27)

The method according to claim 27, characterized in that normalization of results is obtained with the use of the formula:
deltaCt=(Ct miR-1246/miR-150-5p-Ct miR-103-3p).
wherein
deltaCt is a change in the value of threshold cycle
Ct is the value of threshold cycle.

### Claim 29 (depends on 28)

The method according to claim 28, characterized in that the obtained normalized value of deltaCt after comparison with a cut-off point classifies a subject from whom a sample was taken as a subject with or without ovarian cancer.
